Immunogenicity and Safety of One Dose of HPV Vaccine

NCT06345885 | Completed Phase 4

• 1 other identifier: PROPMHP002
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

This study will assess the immunogenicity and safety of one dose of Cecolin and one dose of Gardasil

Conditions

Human Papillomavirus Vaccines

Outcome Measures

Primary Outcomes (1)

• Anti-HPV seropositivity

  Seropositivity to HPV16 and HPV18 types of the neutralizing antibody in subjects will be assessed.

  At 1 month after first dose

Secondary Outcomes (3)

• Anti-HPV Seropositivity

  At 2 months after first dose

• HPV Antibody Titers

  At 1 and 2 months after first dose

• Local and Systemic Reactions/Event

  7 and 30 days after each dose of vaccination; 0-7 months

Study Arms (2)

Group A

EXPERIMENTAL

Bivalent HPV Vaccine (Cecolin)

Biological: HPV vaccine

Group B

ACTIVE COMPARATOR

Quadrivalent HPV vaccine (Gardasil)

Biological: HPV vaccine

Interventions

HPV vaccine BIOLOGICAL

Participants in the group A will be administrated with bivalent HPV vaccine Cecolin. The immunization schedule is 0, 6 months; Participants in the group B will be administrated with quadrivalent HPV vaccine Gardssil. The immunization schedule is 0, 2, 6 months

Group A; Group B

Eligibility Criteria

• Age: 9 Years - 14 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Child (0-17)

You may qualify if:

• Female, aged between 9 and 14 years (including 9 and 14 years) on the day of enrollment
• Judged as healthy and eligible for vaccination by the investigators through a self- reported medical history and some physical examinations
• Subjects and legal guardians are informed and agree, and sign the Informed Consent Form
• Female urine pregnancy test is negative

You may not qualify if:

• Axillary temperature\>37.2 ℃
• Other investigational or unregistered products (drugs or vaccines) that have been used or planned to be used during the study period within 30 days prior to receiving the research vaccine
• Systemic use of immunosuppressants or other immunomodulatory drugs or corticosteroids for a long period of time (lasting for more than 14 days) within 6 months prior to receiving the research vaccine, but local use is allowed (such as ointments, eye drops, inhalers, or nasal sprays)
• Within 3 months prior to vaccination, immunoglobulin and/or blood preparations were used or planned to be used during the study period, but emergency use of tetanus immunoglobulin and rabies immunoglobulin is allowed after exposure
• Received inactivated vaccines within 14 days prior to enrollment in the study, or received live vaccines within 21 days prior to enrollment in the study
• Fever (axillary temperature ≥ 38.0 ℃) within 3 days prior to vaccination, or any acute illness requiring systemic antibiotics or antiviral treatment within the past 5 days
• Previously received HPV vaccine
• Immunodeficiency diseases, chronic medical histories that require treatment for important organs such as primary diseases, cancer (or precancerous lesions), immune diseases (including systemic lupus erythematosus, rheumatoid arthritis, any condition leading to splenectomy or splenectomy, and other immune diseases that researchers believe may have an impact on immune response)
• Have a history of allergies, including serious adverse reactions from previous vaccination, such as allergies, urticaria, breathing difficulties, angiogenic edema, or abdominal pain
• Asthma, with unstable conditions in the past two years requiring emergency treatment, hospitalization, oral or intravenous corticosteroids
• Complicated with serious medical diseases, such as hypertension, heart disease, diabetes, hyperthyroidism, etc
• Abnormal coagulation function (such as coagulation factor deficiency, coagulation disorders, platelet abnormalities) or coagulation disorders diagnosed by doctors
• Epilepsy, excluding febrile epilepsy under 2 years old and simple epilepsy that did not require treatment in the past 3 years
• Due to the inability to comply with research requirements due to psychological conditions, having a past or present mental illness that has not been well controlled within the past two years, requiring medication for mental illness, and having suicidal tendencies in the past five years
• According to the researcher's judgment, due to various medical, psychological, social, occupational factors or other conditions, it is contrary to the research plan or affects the recipient and guardian to sign informed consent

Sponsors & Collaborators

• Xiamen Innovax Biotech Co., Ltd: lead

Study Sites (1)

Fujian Provincial Center for Disease Control and Prevention

Fuzhou, Fujian, 350012, China

Location

Related Publications (1)

• Bergman H, Henschke N, Arevalo-Rodriguez I, Buckley BS, Crosbie EJ, Davies JC, Dwan K, Golder SP, Loke YK, Probyn K, Petkovic J, Villanueva G, Morrison J. Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis. Cochrane Database Syst Rev. 2025 Nov 24;11(11):CD015364. doi: 10.1002/14651858.CD015364.pub2.

  PMID: 41276263 DERIVED

MeSH Terms

Interventions

Papillomavirus Vaccines

Intervention Hierarchy (Ancestors)

Viral Vaccines; Vaccines; Biological Products; Complex Mixtures

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 28, 2024
• First Posted: April 3, 2024
• Study Start: February 23, 2023
• Primary Completion: January 17, 2024
• Study Completion: January 17, 2024
• Last Updated: April 3, 2024

Record last verified: 2024-03

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)